The KP.2-adapted COVID-19 vaccine improves neutralising activity against the XEC variant.
Saved in:
| Title: | The KP.2-adapted COVID-19 vaccine improves neutralising activity against the XEC variant. |
|---|---|
| Authors: | Suthar MS; Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30329, USA; Emory Vaccine Center, Emory University, Atlanta, GA, USA; Emory National Primate Research Center, Atlanta, GA, USA; Department of Microbiology and Immunology, Emory University, Atlanta, GA, USA. Electronic address: msuthar@emory.edu., Manning KE; Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30329, USA; Emory Vaccine Center, Emory University, Atlanta, GA, USA; Emory National Primate Research Center, Atlanta, GA, USA., Ellis ML; Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30329, USA; Emory Vaccine Center, Emory University, Atlanta, GA, USA; Emory National Primate Research Center, Atlanta, GA, USA., Jain S; Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30329, USA; Emory Vaccine Center, Emory University, Atlanta, GA, USA; Emory National Primate Research Center, Atlanta, GA, USA., Bechnak K; Hope Clinic of Emory Vaccine Center, Emory University, Decatur, GA, USA., Vander Velden J; Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30329, USA; Emory Vaccine Center, Emory University, Atlanta, GA, USA; Emory National Primate Research Center, Atlanta, GA, USA., Laboune F; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Henry AR; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Godbole S; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Kim S; Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30329, USA; Emory Vaccine Center, Emory University, Atlanta, GA, USA; Emory National Primate Research Center, Atlanta, GA, USA., Sahoo MK; Stanford University School of Medicine, Stanford, CA, USA., Paredes I; Hope Clinic of Emory Vaccine Center, Emory University, Decatur, GA, USA., Dib SM; Hope Clinic of Emory Vaccine Center, Emory University, Decatur, GA, USA., Kalash S; Hope Clinic of Emory Vaccine Center, Emory University, Decatur, GA, USA., Radi C; Hope Clinic of Emory Vaccine Center, Emory University, Decatur, GA, USA., Hicks H; Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, Atlanta, GA, USA., Tamin A; Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, Atlanta, GA, USA., Gardner M; Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, Atlanta, GA, USA., Bowen N; Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, Atlanta, GA, USA., Cook P; Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, Atlanta, GA, USA., Paden C; Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, Atlanta, GA, USA., Harcourt J; Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, Atlanta, GA, USA., Pinsky BA; Stanford University School of Medicine, Stanford, CA, USA., Douek DC; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Rouphael N; Hope Clinic of Emory Vaccine Center, Emory University, Decatur, GA, USA; Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA., Moreno A; Emory Vaccine Center, Emory University, Atlanta, GA, USA; Emory National Primate Research Center, Atlanta, GA, USA; Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA. Electronic address: camoren@emory.edu. |
| Source: | The Lancet. Infectious diseases [Lancet Infect Dis] 2025 Mar; Vol. 25 (3), pp. e122-e123. Date of Electronic Publication: 2025 Jan 31. |
| Publication Type: | Letter |
| Journal Info: | Publisher: Elsevier Science Country of Publication: United States NLM ID: 101130150 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-4457 (Electronic) Linking ISSN: 14733099 NLM ISO Abbreviation: Lancet Infect Dis Subsets: MEDLINE; In Process |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
